“
TL;DR
The patient's dysphagia was managed with a nasogastric tube, proton pump inhibitors, and eventually a removable esophageal stent implantation, which provided symptom relief.
Medicine · 6 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The patient's dysphagia was managed with a nasogastric tube, proton pump inhibitors, and eventually a removable esophageal stent implantation, which provided symptom relief.
This case report describes a 62-year-old woman with advanced breast cancer who developed esophageal stenosis and ulceration after four cycles of neoadjuvant chemotherapy consisting of albumin paclitaxel, doxorubicin hydrochloride liposome, and cyclophosphamide. The patient presented with severe dysphagia, oral ulcers, and skin changes. Radiological and endoscopic examinations confirmed a severe stricture with ulceration in the middle and lower esophagus, and histological analysis showed inflammatory esophagitis with no tumor cells, indicating a chemotherapy-induced injury. Initial management included a nasogastric tube for nutrition and proton pump inhibitors. Despite nutritional support and subsequent mastectomy, severe dysphagia persisted for over 4 months. A removable esophageal stent was implanted after dilatation failed, which immediately alleviated the patient's symptoms. The report highlights the rarity of this complication and the importance of distinguishing it from esophageal metastasis. The primary limitation is that the specific causative chemotherapeutic agent cannot be definitively identified from this single case.